Tissue Regenix Group plc, a British regenerative medical devices company, has signed seven independent regional sales distribution agreements in the United States. The regional distributors’ represent over 40 sales representatives that will actively promote DermaPure, Tissue Regenix’s dCELL human dermis into acute care hospitals, Veteran Affairs Hospitals and institutions, as well as Long Term Acute Care hospitals in the U.S. DermaPure also remains on course for its commercial launch in the U.S. during the first three months of 2014.
The distribution agreements will now allow Tissue Regenix to promote DermaPure in the following states: Alaska, Washington, Oregon, Idaho, Utah, Montana, New Mexico, Arizona, Minnesota, North Dakota, South Dakota, Wisconsin, Illinois, Texas, Pennsylvania, New York, Maryland, New Jersey, Delaware, Massachusetts, Connecticut, Rhode Island, Vermont, Maine, and New Hampshire.
Tissue Regenix established its American subsidiary, Tissue Regenix Wound Care Inc., in November 2012, as part of its commercialization strategy for its dCELL technology platform. In June this year the operation signed a processing agreement with Community Tissue Services, one of the largest tissue banks in North America. Through the agreement with CTS, Tissue Regenix’s dCELL technology is now being applied to produce DermaPure, for use with acute and chronic wounds. DermaPure works by taking human donor skin and removing the DNA and cells, using the dCELL process to leave a natural biological scaffold that can be placed in the wound to aid natural healing by attracting the patient’s own cells to the wound area.
Release Date: December 12, 2013
Source: Tissue Regenix
